Chemours (CC)
(Delayed Data from NYSE)
$19.79 USD
-0.66 (-3.23%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $19.80 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.79 USD
-0.66 (-3.23%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $19.80 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Zacks News
Why Chemours (CC) Could Beat Earnings Estimates Again
by Zacks Equity Research
Chemours (CC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Analysts Estimate Chemours (CC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemours Gets EPA Nod for Glyclean Cleaner for Coronavirus
by Zacks Equity Research
Chemours (CC) is working closely with customers to ensure that it offers products required for slowing and limiting the spread of the coronavirus.
Why Is Chemours (CC) Up 20.1% Since Last Earnings Report?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chemours (CC) Earnings Beat, Revenues Miss Estimates in Q1
by Zacks Equity Research
Decline volumes in the Fluoroproducts unit and lower global average prices across all segments hurt Chemours' (CC) Q1 sales.
Chemours (CC) Tops Q1 Earnings Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of 39.22% and -2.77%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Chemours (CC) Q1 Earnings Expected to Decline
by Zacks Equity Research
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemours Provides Update in Response to Coronavirus Outbreak
by Zacks Equity Research
Chemours (CC) is likely to use the $300-million proceeds from borrowings in the future for working capital needs or other general corporate purposes.
Are Options Traders Betting on a Big Move in Chemours (CC) Stock?
by Zacks Equity Research
Investors need to pay close attention to Chemours (CC) stock based on the movements in the options market lately.
Here's Why You Should Hold Onto Chemours (CC) Stock Now
by Zacks Equity Research
Chemours (CC) should gain from its actions to drive Opteon adoption and boost productivity across its business segments in 2020.
Chemours (CC) Down 34.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chemours (CC) Inaugurates State-of-the-art Innovation Center
by Zacks Equity Research
Chemours' (CC) new facility is one of Delaware's biggest R&D centers and one of the largest R&D facilities in the chemical industry.
Chemours (CC) Earnings Beat, Revenues Miss Estimates in Q4
by Zacks Equity Research
Lower volumes and prices in Titanium Technologies and Fluoroproducts units hurt Chemours' (CC) Q4 sales.
Implied Volatility Surging for Chemours (CC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Chemours (CC) stock based on the movements in the options market lately.
Chemours (CC) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Our proven model does not predict an earnings beat for Chemours (CC) this season.
Chemours' Opteon XP10 Refrigerants Chosen by Sharc Energy
by Zacks Equity Research
Chemours (CC) anticipates the collaboration to help Sharc Energy engage in refrigerant solutions that are more environmentally sustainable.
Implied Volatility Surging for Chemours (CC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Chemours (CC) stock based on the movements in the options market lately.
Chemours (CC) Down 22.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is the Options Market Predicting a Spike in Chemours (CC) Stock?
by Zacks Equity Research
Investors need to pay close attention to Chemours (CC) stock based on the movements in the options market lately.
Chemours (CC) Earnings Top, Revenues Miss Estimates in Q3
by Zacks Equity Research
Illegal imports of HFC refrigerants and weaker demand for base refrigerants hurt Chemours' (CC) Fluoroproducts unit in Q3.
Chemours (CC) Beats Q3 Earnings Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of 5.36% and -0.19%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Chemours (CC) to Post Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Our proven model does not conclusively predict that Chemours (CC) is likely to beat the Zacks Consensus Estimate this quarter.
Analysts Estimate Chemours (CC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemours (CC) Down 22% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chemours' (CC) Earnings and Revenues Miss Estimates in Q2
by Zacks Equity Research
Weak demand for Ti-Pure TiO2 and Illegal imports of HFC refrigerants hurt Chemours (CC) in Q2.